Interestingly, we found that treatment with Rosiglitazone, a systemic insulin sensitizer which improved cardiac metabolism and function in Atp6v0d1AKO mice (Figure S7), completely restored myocardin expression in Atp6v0d1AKO hearts (Figure 5M-5N), suggesting a causal link between systemic insulin resistance and myocardin downregulation. Here, MYOCD is linked to Insulin resistance.